High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients
Por:
Santos-Garcia, D, Fonticoba, TD, Castro, ES, Diaz, AA, Gonzalez, JMP, Panceiras, MJF, Sancho, CG, Jesus, S, Mir, P, Aguilar, M, Pastor, P, Vara, JH, de Fabregues-Boixar, O, Puente, V, Cuevas, AC, Gonzalez-Aramburu, I, Infante, J, Padilla, FC, Pueyo, M, Escalante, S, Bernardo, N, Solano, B, Foraster, AC, Martinez-Martin, P, Astrid, DA, Almeria, M, Losada, MGA, Canovas, AA, Frech, FA, Sauco, MA, Arnaiz, S, Arribas, S, Vidondo, AA, Avila, MA, Bejr-Kasem, H, Estrada, MB, Boti, M, Borrue, C, Gonzalez, CC, Lopez, IC, Caballol, N, Lorenzo, AC, Carrillo, F, Casas, E, Catalan, MJ, Clavero, P, Fernandez, AC, Cubo, E, Diez-Fairen, M, Erro, E, Peyret, EE, Guillan, NF, Gamez, P, Gallego, M, Caldentey, JG, Campos, CG, Moreno, JMG, Gaston, I, Garre, MPG, Aloy, JG, Ardura, JG, Garcia, BG, Palmas, MJG, Toledo, GRG, Diaz, AG, Sola, MG, Guardia, G, Horta-Barba, A, Kulisevsky, J, Kurtis, M, Labandeira, C, Labrador, MA, Lacruz, F, Castro, ML, Legarda, I, Ariztegui, NL, Diaz, LML, Manzanares, LL, Seoane, BL, Macias, Y, Mata, M, Andres, GM, Marti, MJ, Castrillo, JCM, McAfee, D, Meitin, MT, Gonzalez, MM, del Barrio, CM, Santiago, JM, Casado, MIM, Dieguez, AM, Nogueira, V, Amado, AN, Ponte, SN, Ordas, C, Pagonabarraga, J, Parees, I, Pascual-Sedano, B, Fuertes, AP, Noguera, RP, Planellas, L, Prats, MA, Jurczynska, CP, Rafales, NR, Mendez, LR, Perez, ABR, Roldan, F, De Arcos, MR, Martinez, JR, Alonso, PS, Sanchez-Carpintero, M, Diez, GS, Rodriguez, AS, Santacruz, P, Rodriguez, JCS, Seijo, M, Serarols, A, Pena, MS, Tartari, JP, Valero, C, Vargas, L, Gomez, RV, Vela, L, Villanueva, C, Vives, B, Villar, MD
Publicada:
1 dic 2019
Ahead of Print:
1 oct 2019
Resumen:
C-reactive protein (CRP) is a biomarker of systemic inflammation that has been linked to accelerated decline in walking speed in older adults. The aim of the present study was to compare the CRP levels of PD patients with vs patients without freezing of gait (FOG). Patients and controls participating in the COPPADIS-2015 study that performed blood extraction for determining molecular serum biomarkers were included. Patients with FOG were identified as those with a score of 1 or greater on item-3 of the Freezing of Gait Questionnaire (FOG-Q). Immunoassay was used for determining ultrasensitive CRP (US-CRP) level (mg/dL). In the PD group (n = 225; 61.8 +/- 9.5 years old, 61.8% males), 32% of the patients presented FOG but none in the control group (n = 65; 60.3 +/- 6.1 years old, 56.9% males) (p < 0.0001). Differences in US-CRP level were significant in patients with FOG vs patients without FOG and vs controls (0.31 +/- 0.52 vs 0.16 +/- 0.21 vs 0.21 +/- 0.22; p = 0.04). Significant differences were also observed between patients with vs without FOG (p = 0.001) but not between patients and controls (p = 0.163). US-CRP level was related to FOG (OR = 4.369; 95% CI 1.105-17.275; p = 0.036) along with H&Y (OR = 2.974; 95% CI 1.113-7.943; p = 0.030) and non-motor symptoms burden (NMSS total score; OR = 1.017; 95% CI 1.005-1.029; p = 0.006) after adjusting for age, gender, disease duration, equivalent daily levodopa dose, number of non-antiparkinsonian drugs per day, motor fluctuations, cognition, motor phenotype, and chronic use of anti-inflammatory drugs. The present study suggests that serum US-CRP level is related to FOG in PD patients. Inflammation could be linked to FOG development.
Filiaciones:
Santos-Garcia, D:
CHUAC, Sect Neurol, HUAC, C As Xubias 84, La Coruna 15006, Spain
Fonticoba, TD:
CHUF, Hosp Arquitecto Marcide, La Coruna, Spain
CHUF, Hosp Naval, La Coruna, Spain
Castro, ES:
CHUF, Hosp Arquitecto Marcide, La Coruna, Spain
CHUF, Hosp Naval, La Coruna, Spain
Diaz, AA:
CHUF, Hosp Arquitecto Marcide, La Coruna, Spain
CHUF, Hosp Naval, La Coruna, Spain
Gonzalez, JMP:
CHUAC, Sect Neurol, HUAC, C As Xubias 84, La Coruna 15006, Spain
Panceiras, MJF:
CHUAC, Sect Neurol, HUAC, C As Xubias 84, La Coruna 15006, Spain
Sancho, CG:
CHUAC, Sect Neurol, HUAC, C As Xubias 84, La Coruna 15006, Spain
Jesus, S:
Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, CSIC, Seville, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Mir, P:
Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, CSIC, Seville, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Aguilar, M:
Hosp Univ Mutua Terrassa, Barcelona, Spain
Pastor, P:
Hosp Univ Mutua Terrassa, Barcelona, Spain
Vara, JH:
Hosp Univ Vall dHebron, Barcelona, Spain
de Fabregues-Boixar, O:
Hosp Univ Vall dHebron, Barcelona, Spain
Puente, V:
Hosp del Mar, Barcelona, Spain
Cuevas, AC:
Hosp del Mar, Barcelona, Spain
Gonzalez-Aramburu, I:
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Hosp Univ Marques de Valdecilla, Santander, Spain
Infante, J:
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Hosp Univ Marques de Valdecilla, Santander, Spain
Padilla, FC:
Hosp Univ Canarias, San Cristobal De Laguna, Santa Cruz De T, Spain
Pueyo, M:
Hosp Univ Canarias, San Cristobal De Laguna, Santa Cruz De T, Spain
Escalante, S:
HTVC, Tarragona, Spain
Bernardo, N:
HTVC, Tarragona, Spain
Solano, B:
Inst Catala Salud, IAS, Girona, Spain
Foraster, AC:
Inst Catala Salud, IAS, Girona, Spain
Martinez-Martin, P:
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain
Bejr-Kasem, H:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Horta-Barba, A:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Kulisevsky, J:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
McAfee, D:
University of Maryland School of Medicine, Baltimore, United States
Pascual-Sedano, B:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
|